Literature DB >> 9523526

Adrenalectomy for primary aldosteronism: long-term follow-up study in 29 patients.

J Sirén1, M Välimäki, K Huikuri, A Sivula, P Voutilainen, R Haapiainen.   

Abstract

Primary aldosteronism consists of a mixture of subgroups. The operative treatment is successful only in cases of aldosterone-producing neoplasia (and in rare cases of primary unilateral hyperplasia); all other cases should be treated medically. The aim of this study was to determine if aldosterone-producing neoplasia had been successfully differentiated from the other subgroups and the outcome of operative treatment. Altogether 29 patients with primary aldosteronism were operated on between January 1, 1979 and December 31, 1993. Patient charts were reviewed retrospectively. The follow-up data were collected from the patients' charts, and all patients were contacted to obtain recent blood pressure and serum potassium values. The patients were asked about symptoms related to hyperaldosteronism. If any suspicion of recidive aldosteronism was present, patients were carefully reexamined by hormonal tests and computed tomography (CT). A total of 27 patients had unilateral adenoma, 1 patient had hyperplasia, and 1 patient had an aldosterone-producing cortical carcinoma. There was no operative mortality or morbidity. The serum potassium level had normalized in all patients. Mean follow-up time was 76 months. One patient died during the follow-up from cholangiocarcinoma; 11 patients (41%) were cured by the operation, 10 patients (37%) have a mild but medicated hypertension, and in the remaining 22% the hypertension persisted but was well controlled by the medication. Of the 29 patients, 28 were correctly diagnosed as having an aldosterone-producing neoplasm. Basic hormonal studies and CT can be used effectively to differentiate aldosterone-producing neoplasia from hyperplasia in most cases.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9523526     DOI: 10.1007/s002689900407

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  8 in total

1.  Despite limited specificity, computed tomography predicts lateralization and clinical outcome in primary aldosteronism.

Authors:  G A Kline; V C Dias; B So; A Harvey; J L Pasieka
Journal:  World J Surg       Date:  2014-11       Impact factor: 3.352

2.  Long-term follow-up after adrenalectomy for primary aldosteronism.

Authors:  Andreas Meyer; Georg Brabant; Matthias Behrend
Journal:  World J Surg       Date:  2005-02       Impact factor: 3.352

Review 3.  Treatment of primary aldosteronism: Where are we now?

Authors:  Asterios Karagiannis
Journal:  Rev Endocr Metab Disord       Date:  2011-03       Impact factor: 6.514

4.  The Clinicopathologic Significance of Unilateral Adrenal Cortical Hyperplasia: Report of an Unusual Case and a Review of the Literature.

Authors:  King-Yin Lam; Chung-Yau Lo
Journal:  Endocr Pathol       Date:  1999       Impact factor: 3.943

5.  Long-term results of laparoscopic adrenalectomy for primary aldosteronism.

Authors:  R Campagnacci; F Crosta; A De Sanctis; M Baldarelli; G Giacchetti; A M Paganini; M Coletta; M Guerrieri
Journal:  J Endocrinol Invest       Date:  2009-01       Impact factor: 4.256

6.  Unadjusted Plasma Renin Activity as a "First-Look" Test to Decide Upon Further Investigations for Primary Aldosteronism.

Authors:  Peter Rye; Alex Chin; Janice Pasieka; Benny So; Adrian Harvey; Gregory Kline
Journal:  J Clin Hypertens (Greenwich)       Date:  2015-03-10       Impact factor: 3.738

7.  Rare normalization of blood pressure after unilateral adrenalectomy in 31 patients with Conn syndrome.

Authors:  Jacek Ziaja; Jerzy Chudek; Robert Król; Jacek Pawlicki; Andrzej Wiecek; Lech Cierpka
Journal:  Langenbecks Arch Surg       Date:  2007-01-26       Impact factor: 2.895

8.  Outcome of patients undergoing laparoscopic adrenalectomy for primary hyperaldosteronism.

Authors:  Brian K P Goh; Yeh-Hong Tan; Sidney K H Yip; Peter H K Eng; Christopher W S Cheng
Journal:  JSLS       Date:  2004 Oct-Dec       Impact factor: 2.172

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.